NCT00687934

Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors

A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered Once-Weekly in Patients With Solid Tumors

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 53 (actual)
• Sponsor: Synta Pharmaceuticals Corp. · Industry
• Sex: All
• Age: 25 Years
• Healthy volunteers: Not accepted

Summary

An open-label dose escalation study of patients with solid tumors treated with STA-9090 (ganetespib)

Conditions

• Solid Tumors

Interventions

Type	Name	Description
DRUG	STA-9090	This is a dose-escalation study. The first cohort will consist of three patients who will receive STA 9090 (ganetespib)during a 1-hour infusion once per week for three consecutive weeks followed by a 1 week dose-free interval. Subsequent cohorts will receive higher amounts of STA-9090 (gantespib) provided that the previous dose was well tolerated during cycle 1 (week 1 - 4). Dose escalation will continue until the maximum tolerated dose (MTD) is determined.

Timeline

• Start date: 2007-10-01
• Primary completion: 2011-06-01
• Completion: 2011-10-01
• First posted: 2008-06-02
• Last updated: 2014-09-18

Locations

2 sites across 1 country: United States